Abstract
This review provides insight into two clinical trials conducted with ex vivo manipulated CD34+ cells. The first was an atempt to deliver a gene therapy for treatment of HIV and the second an attempt to improve rates of hemopoietic recovery with ex vivo generated myeloid cells.